BRIDGEWAY CAPITAL MANAGEMENT, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 96 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2019. The put-call ratio across all filers is 0.68 and the average weighting 0.1%.

Quarter-by-quarter ownership
BRIDGEWAY CAPITAL MANAGEMENT, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$922,484
-16.3%
781,7660.0%0.02%
-15.4%
Q2 2023$1,102,290
-6.0%
781,7660.0%0.03%
-16.1%
Q1 2023$1,172,649
+28.2%
781,7660.0%0.03%
+29.2%
Q4 2022$914,666
+235.0%
781,766
+223.5%
0.02%
+242.9%
Q3 2022$273,000
-56.2%
241,666
-38.7%
0.01%
-50.0%
Q2 2022$623,000
+2608.7%
394,366
+2589.0%
0.01%
Q1 2022$23,000
-95.7%
14,666
-93.2%
0.00%
-100.0%
Q4 2021$532,000
-7.5%
217,266
-4.8%
0.01%
-9.1%
Q3 2021$575,000
-66.2%
228,266
-61.7%
0.01%
-63.3%
Q2 2021$1,700,000
+12.5%
596,427
-7.3%
0.03%
+7.1%
Q1 2021$1,511,000
+26.1%
643,139
-5.5%
0.03%
+12.0%
Q4 2020$1,198,000
+119.0%
680,839
+16.5%
0.02%
+92.3%
Q3 2020$547,000
+37.1%
584,539
+27.6%
0.01%
+62.5%
Q2 2020$399,000
-8.9%
458,060
-13.4%
0.01%
-20.0%
Q1 2020$438,000
-7.0%
529,0390.0%0.01%
+66.7%
Q4 2019$471,000
-9.1%
529,0390.0%0.01%
-14.3%
Q3 2019$518,000529,0390.01%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2019
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$55,198,0004.16%
Raffles Associates 1,930,536$3,050,0003.32%
Defender Capital, LLC. 5,131,935$8,108,0003.18%
Prescott General Partners LLC 1,851,851$2,926,0000.20%
DAFNA Capital Management LLC 140,000$221,0000.06%
Laurion Capital Management LP 2,422,367$3,827,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$71,0000.05%
Fort Sheridan Advisors LLC 78,931$125,0000.04%
Long Focus Capital Management, LLC 215,000$340,0000.04%
MORGAN JESS S & CO INC 20,000$32,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders